Skip to main content
. 2017 Feb 15;7:42706. doi: 10.1038/srep42706

Table 1. Characterization of the subjects.

Patient Age yr BMI kg/m2 Diagnosis Diagnostic test GH peak μg/l GH dose mg daily HbA1c
Insufficient pituitary axes
mmol/mol %
1 68 32.8 Pituitary apoplexy Insulin tolerance test 0.08 0.15 34 5.3 GH, T, C, Gn
2 67 26.4 Pituitary apoplexy Insulin tolerance test 0.99 0.4 41 5.9 GH, T, C, Gn
3 26 26.0 Congenital hypopituitaism GHRH plus arginine stimulation test 1.61 0.3 36 5.4 GH, T, C
4 48 31.7 Pituitary apoplexy Insulin tolerance test 0 0.5 39 5.7 GH, T, C, Gn
5 67 27.0 Pituitary adenoma, surgical treatment and radiotherapy Insulin tolerance test 0.41 0.2 41 5.9 GH, T, C, Gn
6 52 30.4 Clinically nonfunctioning pituitary adenoma Arginine stimulation test 1.12 0.3 40 5.8 GH, T, C, Gn
7 50 25.8 Pituitary cyst, surgical treatment Insulin tolerance test 0.20 0.3 33 5.2 GH, T, C, Gn
8 42 42.0 Traumatic brain injury Arginine stimulation test 0.13 0.3 30 4.9 GH, T, C, Gn

BMI, body mass index; IGF-I levels at baseline during GH substition. GH, growth hormone; T, thyrotropin; C, corticotropin; Gn, gonadotropin.